Researchers Identified Genetic Signature Predicting Melanoma
A new six-gene study reveals molecular markers that reliably predict the likelihood of melanoma relapse in patients.
Updated on Sept. 29, 2026 in Cancer
Live Poll
Do you believe new genetic research methods will significantly improve future cancer treatment outcomes?
Scientists have discovered a six-gene copy-number signature known as OncoCycle that predicts melanoma relapse. The findings indicate that metastatic progression is driven by copy-number evolution and specific genetic losses.
Why it matters
Identifying metastatic competence early is crucial for improving patient outcomes. This signature predicts relapse independently of standard clinical features, potentially allowing for more personalized intervention strategies.
The OncoCycle signature consists of the amplification of CDK4, MCL1 and CD276 alongside the biallelic loss of CDKN2A, CDKN2B and TP53BP1. This genomic profile was identified through a study of 247 primary melanomas and 60 matched metastases.
The players
Columbia University
This academic institution provided the research affiliation for the team that conducted the study.
The details
Researchers utilized sequencing to integrate copy-number, mutational, protein, and spatial-transcriptomic analyses to identify metastatic subclones within immune and stromal niches. The study found that metastatic competence was primed early by focal somatic copy-number alterations occurring on a background of chromosomal instability.
Timeline
The study cohort maintained a median follow-up period of 92 months.
Health Landscape
This study advances the foundational genomic mapping established by the Cancer Genome Atlas (TCGA) melanoma sequencing standards. The findings represent a shift toward utilizing specific copy-number signatures to anticipate tumor progression rather than relying solely on traditional staging.
The development of this signature may eventually lead to more accurate risk assessments and personalized monitoring plans for those diagnosed with primary cutaneous melanoma. It could influence how clinicians prioritize follow-up care and early detection of potential relapses.
The takeaway
This discovery highlights the importance of analyzing tumor genomic evolution to anticipate metastatic behavior. Patients should discuss the role of genetic testing with their oncologists to understand how molecular signatures may influence their long-term care plans.
Further reading
For more information on current developments in oncology, visit the Cancer research section.
More information
Read the detailed findings in the biorxiv research article.
Live Poll
Do you believe new genetic research methods will significantly improve future cancer treatment outcomes?
